Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

LabCorp & Interpace Team Up, Drive Specialty Diagnostics

Per the new deal with Interpace, Dianon Pathology, member of the LabCorp (LH) Specialty Testing Group, is supposed to perform the thyroid biopsy analysis.

    DaVita (DVA) Banks on Kidney Care Unit Amid Labor Union Woes

    Davita's kidney care unit is gaining prominence worldwide. However, the company is grappling with labor-union woes in California and Ohio.

      Varian Medical's ProBeam Platform Gains Traction in Russia

      Varian Medical's (VAR) ProBeam system is a leading platform in advanced cancer-care technologies.

        CVS Health's Pharmacy Services Remain Solid Amid Retail Drag

        CVS Health's (CVS) robust 2018 PBM selling season is an upside. We are also upbeat about the company's initiation of the crucial $69-billion acquisition of Aetna.

          Thermo Fisher Scientific Buys IntegenX, Widens HID Suite

          Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.

            What's Driving Orthofix International to a New 52-Week High

            Orthofix International is (OFIX) strong on recent buyouts as well as the FDA approval.

              BioScrip's Dull 2017 Earnings a Woe, Core Business Robust

              BioScrip's (BIOS) strategy to specifically focus on core revenue mix hurts overall growth. However, the company's core infusion business remains strong.

                Orthofix to Buy Spinal Kinetics, Widens Spine Fixation Suite

                Orthofix's (OFIX) latest deal to boost Spine Fixation portfolio and strengthen hold in the high-potential artificial disc market buoys optimism.

                  Here's Why You Should Invest in Varian Medical Right Now

                  Varian Medical (VAR) banks on regulatory tidings and acquisition.

                    Here's Why You Should Invest in AmerisourceBergen Right Now

                    AmerisourceBergen's (ABC) consistent pursuit of acquisitions to strengthen core areas buoys optimism.

                      QIAGEN's QFT-Plus Endorsed for Latent Tuberculosis Screening

                      QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.

                        Varian Medical Receives Regulatory Nod for Sirtex Buyout

                        The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.

                          Medtronic's (MDT) Guardian Connect CGM System Wins FDA Nod

                          Medtronic (MDT) continues to add initiatives to bolster the Diabetes segment.

                            Cooper Companies Banks on Specialty Lenses, Competition Rife

                            Cooper Companies' (COO) flagship silicone hydrogel lenses are expected to see strong sales in the quarters ahead.

                              Medtronic's Positive Study Results May Boost CSH Business

                              Medtronic, (MDT) presenting favorable results from the studies based on the CoreValve TAVR system might boost the top line, with increased uptake of the product.

                                Laborie Medical Technologies to Acquire Cogentix Medical

                                Laborie Medical Technologies will buy all of the outstanding shares of Cogentix Medical (CGNT) for a net worth of $239 million.

                                  Illumina Banks on Product Launches & Strategic Partnerships

                                  Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.

                                    Accuray Gains on Radixact Unit, Solid Geographical Foothold

                                    Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).

                                      ABIOMED (ABMD) Banks on Impella Platform, Competition Rife

                                      Impella, ABIOMED's (ABMD) flagship product line, continues to be growth driver.

                                        Varian (VAR) to Equip 7 Centers in Mexico, Expand in Oncology

                                        Varian's (VAR) Edge radiosurgery system will allow physicians to treat tumors noninvasively in Mexico.

                                          IDEXX Laboratories Gains on Solid Prospects & CAG Business

                                          IDEXX Laboratories (IDXX) continues to boost investor confidence in strong companion animal business along with attractive global prospects.

                                            BioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise

                                            BioScrip's (BIOS) strategic shift toward raising its core revenue mix hampers growth. However, guidance for 2018 buoys optimism on the stock.

                                              GNC Holdings Expands in India, Boosts International Business

                                              GNC Holdings (GNC) adopts initiatives to increase contributions from international business.

                                                Cooper Companies (COO) Tops Q1 Earnings & Revenue Estimates

                                                Cooper Companies (COO) Q1 results gain from strength in CooperVision segment.

                                                  4 Factors Driving Edwards Lifesciences to a New 52-Week High

                                                  Edwards Lifesciences (EW) strong on recent buyouts and CE Mark.